Home - ExecEdge

The Cancer Therapy Strategy VERAXA Is Betting the Company On

The Cancer Therapy Strategy VERAXA Is Betting the Company On

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline...

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial

The Cancer Therapy Strategy VERAXA Is Betting the Company On

The Cancer Therapy Strategy VERAXA Is Betting the Company On

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial

Tackling the AI Security Crisis: Pax8’s Rob Belgrave and SentinelOne’s Steve Stone, Live from Pax8 Beyond 2026

Tackling the AI Security Crisis: Pax8’s Rob Belgrave and SentinelOne’s Steve Stone, Live from Pax8 Beyond 2026

Human-led Management of Autonomous Digital Workers: Pax8 Global Sr Director Renee McCloden, Halo CCO Tim Barton-Wines, Live from Pax8 Beyond 2026

Human-led Management of Autonomous Digital Workers: Pax8 Global Sr Director Renee McCloden, Halo CCO Tim Barton-Wines, Live from Pax8 Beyond 2026

The AI Race Has Changed: How MSPs Drive Growth for SMBs: Pax8 CSO Ryan Walsh, possibl.ai CEO Nyssa Waters, Live from Pax8 Beyond 2026

The AI Race Has Changed: How MSPs Drive Growth for SMBs: Pax8 CSO Ryan Walsh, possibl.ai CEO Nyssa Waters, Live from Pax8 Beyond 2026

Input your search keywords and press Enter.